Reports Q4 revenue $71.2M, consensus $68.01M. "Our fourth quarter performance caps off a successful year of execution and key milestone achievement despite reimbursement headwinds and a challenging macroeconomic environment," said Thomas Burns, Glaukos chairman and chief executive officer. "We continue to successfully invest in and advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GKOS:
- Glaukos announces clinical updates for several corneal disorders
- Glaukos announces positive results for iDose TR exchange trial
- Castle Biosciences, Academy Sports on Stephens ‘Best Ideas’ list for 2023
- Stephens carries over seven stocks to ‘Best Ideas’ list for 2023
- Glaukos price target lowered to $68 from $69 at Stephens